Search

Boehringer Ingelheim Enters Clinical Collaboration with Amgen to Study BI 1701963, a SOS1::pan-KRAS Inhibitor, in Combination with LUMAKRAS™ (sotorasib), a KRASG12C Inhibitor

Boehringer Ingelheim and OSE Immunotherapeutics Announce Global Immuno-Oncology Partnership to Develop a Pioneering Checkpoint Inhibitor for the Treatment of Advanced Solid Tumors

Numab Therapeutics and Boehringer Ingelheim Enter into Collaboration to Develop Multi-specific Antibody Therapeutics for Cancer and Retinal Diseases

Boehringer Ingelheim and Lilly Announce Clinical Trial Collaboration in Metastatic Breast Cancer

Boehringer Ingelheim and Vanderbilt University join forces to develop new Ras inhibitors for cancer treatment

Boehringer Ingelheim and Vanderbilt University join forces

Boehringer Ingelheim and Yale Clinical and Translational Research Accelerator collaborate to explore potential benefits of digital health technologies for adults with heart failure

Boehringer Ingelheim Announces the Launch of Centragard™ (eprinomectin and praziquantel transdermal solution), Innovative Internal Parasite Protection For Cats

Boehringer Ingelheim Celebrates 50th Anniversary in the U.S. by Committing Up to $450,000 to Nonprofit Partners

ATS Announces that BI is First Donor of COVID-19 Fund | Boehringer Ingelheim US

American Thoracic Society Announces that Boehringer Ingelheim is the first donor of its COVID‐19 Crisis Fund

Boehringer Ingelheim Advances Novel Bi-specific TRAILR2/CDH17 Antibody to Phase 1 Clinical Trial for Patients Living with Gastrointestinal Cancers

First half of 2021: Boehringer Ingelheim makes fundamental progress in research and development

Boehringer Ingelheim Pharmaceuticals, Inc. receives FDA approval for CyltezoTM (adalimumab-adbm)

Cyltezo® (adalimumab-adbm) Patent Litigation Resolution| BI US

Read more about Boehringer Ingelheim's CYLTEZO patent litigation resolution, meaning greater access to the treatment for patients across the USA.

Heartworm Disease Prevention Initiative | Boehringer Ingelheim USheartworm disease prevention through its Heartworm 2020 initiative

Read more on how the Boehringer Ingelheim heartworm disease prevention initiative has helped more than 51,000 dogs receive care across the USA in 2020.

Company History | Corporate Profile | Boehringer Ingelheim US

Click here to watch our video on the history of Boehringer Ingelheim, founded by Albert Boehringer in 1885.

Boehringer Ingelheim Expands KRAS Cancer Program with Lupin’s Clinical Stage MEK Inhibitor Compound

Boehringer Ingelheim Expands KRAS Cancer Program with Lupin’s Clinical

Boehringer Ingelheim and the Atlanta Humane Society mark the grand opening of a unique pet adoption center in Metro Atlanta

Boehringer Ingelheim Partners with Enleofen to Develop First-in-Class Anti-IL-11 Therapies for a Range of Fibrotic Diseases

Boehringer Ingelheim’s Investigational Therapy Nintedanib Receives FDA Breakthrough Therapy Designation

Boehringer Ingelheim and Zealand Pharma Advance to Phase 2 Clinical Testing in NASH and Obesity

Boehringer Ingelheim and University of Dundee Highlight Successful PROTAC Drug Discovery Program and Extend Their Ongoing Anti-Cancer Alliance

FDA Approves Boehringer Ingelheim’s Striverdi® Respimat® (olodaterol) Inhalation Spray for Maintenance Treatment of COPD

Boehringer Ingelheim Vetmedica, Inc. to Establish North America and U.S. Headquarters in Duluth, Ga. Following Close of BI/Sanofi Asset Swap

Boehringer Ingelheim and Gubra announce new collaboration to develop anti-obesity peptide poly-agonists

Quantum Computing: Boehringer Ingelheim and Google Partner for Pharma R&D

About Us

Human Health

Animal Health

Science & Innovation

Partnering

Careers